The Excipients between Effects and the Side Effects
Article Sidebar
-
excipients binders lubricants alcohol acids organic
Abstract
Most of the medicines contain excipients. They are added for a number of purposes and can improve product performance, including enabling formulations, the patient's acceptance and compliance, There are numerous examples of typical excipients affecting drug absorption. For example, carbohydrates and phosphoric acid delay gastric emptying, due to their caloric content and pH, respectively, and affect the saturable absorption of riboflavin and the saturable biotransformation of salicylamide, The effect of reactions between the active pharmaceutical substance and the excipients could be a reduction in drug concentration, but at the same time unknown structure and biological activity would appear and, in the worst case, this could lead to adverse effects, the aim of this review is to explore excipients function and the possible side effects associated with it . conclusion: the potential adverse effect of the excipients should not be underestimated and a periodic review and follow up of side effects that may appear and occur after a drug administration should not be limited to the active medication in the drug formula but also the excipient should be taken into account.
Full text article
References
Pharmaceutical excipients — quality, regulatory and biopharmaceutical considerations, David P. Elder et al. European Journal of Pharmaceutical Sciences
Dorothy Chang, Ron Kun Chang” review of current issue in pharmaceutical excipients” may 2 2007, available on www.pharmtech findpedia.com.
Lakshmana Pramod et.al” global regulatory perspective of bulk pharmaceutical excipients” available on www.pharmainfo.net/ review/global regulatory perspective-bulk-pharmaceutical – excipients.
Patrick J Crowley, Luigi G Martini “excipients for pharmaceutical dosage forms” Encyclopedia of pharmaceutical technology 02 oct 2006. Available at www.informaworld.com.
Lokesh Bhattacharyya, Stefan Schuber, Catherine Sheehan, and Roger William “Excipients: background/introduction” Excipient development for pharmaceutical biotechnology and drug delivery systems; Ashok Katdare , Mahesh V. Chaubal (ed) ©by Informa Healthcare USA, Inc, 2006;1-2.
Giorgio Pifferi, Patrizia Restani” the safety of pharmaceutical excipients” farmaco 58 (8) 541-550 (2003).
Sari Airaksinen et.al” excipient selection can significantly affect solid state phase transformation in formulation during wet granulation” apps pharmscitech, 2005, 6(2), E 311-E 322, DOI10.12081 pt 060241
Rowe, R.C., Sheskey, P.J., Cook,W.G., Fenton, M.E., 2012. Handbook of pharmaceutical excipients. 7th Edition. Pharmaceutical press, London.
De Jong, H.J., 1999. The safety of pharmaceutical excipients. Therapie 54, 11–14.
Elder, D., Kuentz, M. and Holm, R. (2016). Pharmaceutical excipients — quality, regulatory and biopharmaceutical considerations. European Journal of Pharmaceutical Sciences, 87, pp.88-99.
Darji, M., Lalge, R., Marathe, S., Mulay, T., Fatima, T., Alshammari, A., Lee, H., Repka, M. and Narasimha Murthy, S. (2017). Excipient Stability in Oral Solid Dosage Forms: A Review. AAPS PharmSciTech, 19(1), pp.12-26.
Lachman L, Liebermann HA, Kanig JL, editors. The theory and practice of industrial pharmacy. 3rd ed. Philadelphia: Lea & Febiger; 1986. p. 902.
Jarosz PJ, Parrott EL. Effect of lubricants on tensile strengths of tablets. Drug Dev Ind Pharm. 1984;10(2):259–73. Miller T, York P. Pharmaceutical tablet lubrication. Int J Pharm. 1988;41(1–2):1–19.
IPEC, 14-15th May, 1998. Excipients in pharmaceutical dosage forms: The challenge of the 21st century. IPEC (International Pharmaceutical Excipients Council), Nice
USP. Excipient Biological Safety Evaluation Guidelines b1074N.
Russell, R., 2004. Synthetic excipients challenge all natural organics — offer advantages/challenges to developers and formulators. Pharm. Technol.
García-Arieta, A. (2014). Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: Impact on bioequivalence. European Journal of Pharmaceutical Sciences, 65, pp.89-97
Wempe, M.F., Wright, C., Little, J.L., Lightner, J.W., Large, S.E., Caflisch, G.B., Buchanan, C.M., Rice, P.J., Wacher, V.J., Ruble, K.M., Edgar, K.J., 2009. Inhibiting efflux with novel non-ionic surfactants: rational design based on vitamin E TPGS. Int. J. Pharm. 370, 93–102.
Kato, R., Takanaka, A., Onoda, K., Omori, Y., 1969. Effect of syrup on the absorption of drugs from gastrointestinal tract. Jpn. J. Pharmacol. 19, 331–342
Houston, J.B., Levy, G., 1975. Effect of carbonated beverages and of an antiemetic containing carbohydrate and phosphoric acid on riboflavin bioavailability and salicylamide biotransformation in humans. J. Pharm. Sci. 64, 1504–1507
Kelly, K., O’Mahony, B., Lindsay, B., Jones, T., Grattan, T.J., Rostami-Hodjegan, A.,Stevens, H.N., Wilson, C.G.,Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation using gamma scintigraphy. Pharm. Res. 20, 1668–1673
Larocque, G., Arnold, A.A., Chartrand, E., Mouget, Y., Marcotte, I., 2010. Effect of sodium bicarbonate as a pharmaceutical formulation excipient on the interaction of fluvastatin with membrane phospholipids. Eur. Biophys. J. 39, 1637–1647.
Koch, K.M., Parr, A.F., Tomlinson, J.J., Sandefer, E.P., Digenis, G.A., Donn, K.H., Powell, J.R., 1993. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm. Res. 10, 1027–1030.
Adkin, D.A., Davis, S.S., Sparrow, R.A., Huckle, P.D., Phillips, A.J., Wilding, I.R.. The effect of different concentrations of mannitol in solution on small intestinal transit: implications for drug absorption. Pharm Res. 12, 393–396.
Schulze, J.D., Ashiru, D.A., Khela, M.K., Evans, D.F., Patel, R., Parsons, G.E., Coffin, M.D., Basit, A.W., 2006. Impact of formulation excipients on human intestinal transit. J. Pharm. Pharmacol. 58, 821–825.
Basit, A.W., Podczeck, F., Newton, J.M., Waddington, W.A., Ell, P.J., Lacey, L.F., 2002. Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine. Pharm. Res. 19, 1368–1374.
Ashiru, D.A., Patel, R., Basit, A.W., 2008. Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. Pharm. Res. 25, 2327–2333.
Ashiru-Oredope, D.A., Patel, N., Forbes, B., Patel, R., Basit, A.W., 2011. The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers. Int. J. Pharm. 409, 164–168.
Shen, Q., Lin, Y., Handa, T., Doi, M., Sugie, M., Wakayama, K., Okada, N., Fujita, T., Yamamoto, A., 2006. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int. J. Pharm. 313, 49–56.
Yuen, G.J., Morris, D.M., Mydlow, P.K., Haidar, S., Hall, S.T., Hussey, E.K., 1995. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35, 1174–1180.
Kasirye, P., Kendall, L., Adkison, K.K., Tumusiime, C., Ssenyonga, M., Bakeera-Kitaka, S., Nahirya-Ntege, P., Mhute, T., Kekitiinwa, A., Snowden, W., Burger, D.M., Gibb, D.M., Walker, A.S., 2012. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin. Pharmacol. Ther. 91, 272–280.
[Buch, P., Holm, P., Thomassen, J.Q., Scherer, D., Branscheid, R., Kolb, U., Langguth, P., 2010. IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics. J. Pharm. Sci. 99, 4427–4436.
[Oda, M., Saitoh, H., Kobayashi, M., Aungst, B.J., 2004. Beta-cyclodextrin as a suitable solubilizing agent for in situ absorption study of poorly water-soluble drugs. Int. J. Pharm. 280, 95–102.
Kalitsky-Szirtes, J., Shayeganpour, A., Brocks, D.R., Piquette-Miller, M., 2004. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug. Metab. Dispos. 32, 20–27.
El-Masry, E.M., Abou-Donia, M.B.. Reversal of P-glycoprotein expressed in Escherichia coli leaky mutant by ascorbic acid. Life Sci. 73, 981–991
[Li, Y.H., Zhang, M., Wang, J.C., Zhang, S., Liu, J.R., Zhang, Q., 2006. Effects of absorption enhancers on intestinal absorption of lumbrokinase. Yao Xue Xue Bao 41, 939–944
Sinha V.R., Rachna K.. Polysaccharides in colon specific drug delivery. Int. J. Pharm.
Cyclodextrins: Application in different routes of drug administration SHYAM SHIMPI1* BHASKAR CHAUHAN1 PRAJAKTA SHIMPI2.
Cyclodextrin Enhances Corneal Tolerability and Reduces Ocular Toxicity Caused by Diclofenac.
Stutchbury TK, Vine KL, Locke JM, Chrisp JS, Bremner JB, et al. (2011) Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Anticancer Drugs 22: 24-34
Potential Impact of CyclodextrinContaining Formulations in Toxicity Evaluation of Novel Compounds in Early Drug Discovery, Umesh M Hanumegowda*, et al. Department of Discovery Toxicology, Bristol-Myers Squibb Research and Development.
Reaction between drug substances and pharmaceutical excipients: formation of citric acid esters and amides of carvedilol in the solid state J. Larsen, et al. Biomed.
Trace determination of ethyl methanesulfonate in Viracept 250mg tablets by gas chromatography–mass spectrometry, H. Rebiere, et al. Sci. Notes.
The Safety Committee of the Int. Pharmaceutical Excipients Council, Regul. Toxicol. Pharmacol. 24 (1996) 149
(a) JEFCA, Joint FAO/WHO Expert Committee on FoodAdditives, 22nd Technical Report Series (1989) 776.;(b) JEFCA, Joint FAO/WHO Expert Committee on FoodAdditives, 33rd Technical Report Series, 1995, p. 859.;(c) JEFCA, Joint FAO/WHO Expert Committee on food additives.
Addressing specific regulatory excipient requirements in themarketing authorization Hebestreit, P., 2009. The International Pharmaceutical Excipients Council Meeting, Nice.
Paediatric pharmacology: remember the excipients. Pharmacol Fabiano et al, G.V., 2011. Res. 63, 362–365
Lim, T. Y., Poole, R. L., & Pageler, N. M. (2014). Propylene glycol toxicity in children. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 19(4), 277-82
American Academy of Pediatrics Committee on Drugs. ‘‘Inactive’’ ingredients in pharmaceutical products: update (subject review).
Pawar S, Kumar A. Issues in the formulation of drugs for oral use in children. Pediatr Drugs;4:371–9.
Probable adverse reaction to a pharmaceutical excipient C M Hall, D W A Milligan, J Berrington.
Effects of aspartame metabolites on astrocytes and neurons, Karol Rycerz, Jadwiga Elżbieta Jaworska-Adamu. Department of Animal Anatomy and Histology, Faculty of Veterinary Medicine, University of Life Sciences, Lublin, Poland.
Ranjan, Shivendu & Chidambaram, Ramalingam. (2016). Titanium dioxide nanoparticles induce bacterial membrane rupture by reactive oxygen species generation. Environmental Chemistry Letters. 14. 10.1007/s10311-016-0586-y.
Christina L. Wilson et al, Mitochondrial Dysfunction and Loss of Glutamate Uptake in Primary Astrocytes Exposed to Titanium Dioxide Nanoparticles.
Excipients and additives: hidden hazards in drug products and in product substitution, E. Napke et al.
Metabisulfite sensitivity: case report and literature review, W.A. Jameson, M.F. Guill, B.B. Wray
Pharmacist’s Role in Managing Special Patient Needs Related to Excipients, Lindsay Snyder et al.
Baffi, P & Elneser, S & Baffi, M & De Melin, M. Quantitative determination of diethylene glycol contamination in pharmaceutical products. Journal of AOAC International. 83. 793-801
EXCIPIENT-RELATED ADVERSE DRUG REACTIONS: A CLINICAL APPROACH, J Strauss et al. Department of Pharmacology, University of Pretoria.
J. Lasset al, Hospitalised neonates in Estonia commonly receive potentially harmful excipients.
K. Allegaert, S. Vanhaesebrouck, A. Kulo, K.Cosaert, R. Verbesselt, A. Debeer, J. de HoonProspective assessment of short-term propylene glycol tolerance in neonates.
The gasping syndrome and benzyl alcohol poisoning, Gershanik J. N Engl J Med 1982;307:1384–8.
Probable adverse reaction to a pharmaceutical excipient, C M Hall, D W A Milligan, J Berrington. Arch Dis Child Fetal Neonatal Ed 2004;89:F184. doi: 10.1136/adc.2002.024927